The authors of this study suggest the importance of establishing the underlying MMR gene mutations in individuals with aggressive pituitary tumors since they may be subject to ICPI therapy, mainly seen with other LS-related tumors [89]. The gene discussed is MRC1; the disease is pituitary tumor.